# A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

> **NCT03820726** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 435 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03820726
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820726, "A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03820726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*